{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:10:34Z","timestamp":1792440634754,"version":"4.5.0"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.addr.2024.115283","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T02:57:25Z","timestamp":1710557845000},"page":"115283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["RNA therapies for CNS diseases"],"prefix":"10.1016","volume":"208","author":[{"given":"Valentina","family":"Di Francesco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy J.","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin S.","family":"Bleier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-881X","authenticated-orcid":false,"given":"Mansoor M.","family":"Amiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2024.115283_b0005","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.952161","article-title":"Global, regional, and national burden and attributable risk factors of neurological disorders: the global burden of disease study 1990\u20132019","volume":"10","author":"Ding","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.addr.2024.115283_b0010","doi-asserted-by":"crossref","unstructured":"Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019, 18 (5), 459-480. DOI: 10.1016\/s1474-4422(18)30499-x From NLM.","DOI":"10.1016\/S1474-4422(18)30499-X"},{"key":"10.1016\/j.addr.2024.115283_b0015","doi-asserted-by":"crossref","unstructured":"Li, X.; Feng, X.; Sun, X.; Hou, N.; Han, F.; Liu, Y. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2019. Front Aging Neurosci 2022, 14, 937486. DOI: 10.3389\/fnagi.2022.937486 From NLM. Zhong, Q. Q.; Zhu, F. Trends in Prevalence Cases and Disability-Adjusted Life-Years of Parkinson's Disease: Findings from the Global Burden of Disease Study 2019. Neuroepidemiology 2022, 56 (4), 261-270. DOI: 10.1159\/000524208 From NLM.","DOI":"10.1159\/000524208"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0020","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/15476286.2022.2066334","article-title":"Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases","volume":"19","author":"Holm","year":"2022","journal-title":"RNA Biol"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0025","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/15476286.2021.2021650","article-title":"RNA-based therapeutics for neurological diseases","volume":"19","author":"Anthony","year":"2022","journal-title":"RNA Biol"},{"issue":"4","key":"10.1016\/j.addr.2024.115283_b0030","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1261\/rna.079626.123","article-title":"RNA therapeutics","volume":"29","author":"Hastings","year":"2023","journal-title":"Rna"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood-brain barrier: structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.addr.2024.115283_b0040","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: an overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.addr.2024.115283_b0045","doi-asserted-by":"crossref","unstructured":"Gotte, G.; Menegazzi, M. Biological Activities of Secretory RNases: Focus on Their Oligomerization to Design Antitumor Drugs. Front Immunol 2019, 10, 2626. DOI: 10.3389\/fimmu.2019.02626 From NLM. Sorrentino, S. The eight human \u201ccanonical\u201d ribonucleases: molecular diversity, catalytic properties, and special biological actions of the enzyme proteins. FEBS Lett 2010, 584 (11), 2194-2200. DOI: 10.1016\/j.febslet.2010.04.018 From NLM.","DOI":"10.1016\/j.febslet.2010.04.018"},{"key":"10.1016\/j.addr.2024.115283_b0050","doi-asserted-by":"crossref","unstructured":"Wu, S.; Liu, C.; Bai, S.; Lu, Z.; Liu, G. Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy. Bioengineering (Basel) 2022, 9 (10). DOI: 10.3390\/bioengineering9100576 From NLM.","DOI":"10.3390\/bioengineering9100576"},{"issue":"23","key":"10.1016\/j.addr.2024.115283_b0055","doi-asserted-by":"crossref","first-page":"20234","DOI":"10.1021\/acsomega.3c01703","article-title":"Emergence of small interfering RNA-based gene drugs for Various diseases","volume":"8","author":"Kurakula","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.addr.2024.115283_b0060","article-title":"Not making the cut: techniques to prevent RNA cleavage in structural studies of RNase-RNA complexes","volume":"6","author":"Jones","year":"2022","journal-title":"J Struct Biol X"},{"issue":"4","key":"10.1016\/j.addr.2024.115283_b0065","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1089\/nat.2012.0350","article-title":"Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology","volume":"22","author":"Guo","year":"2012","journal-title":"Nucleic Acid Ther"},{"issue":"16","key":"10.1016\/j.addr.2024.115283_b0070","doi-asserted-by":"crossref","first-page":"e2101090","DOI":"10.1002\/advs.202101090","article-title":"Development of novel therapeutics Targeting the blood-brain Barrier: from Barrier to Carrier","volume":"8","author":"Li","year":"2021","journal-title":"Adv Sci (weinh)"},{"issue":"9","key":"10.1016\/j.addr.2024.115283_b0075","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1007\/s11095-007-9321-5","article-title":"Blood-brain barrier transport of non-viral gene and RNAi therapeutics","volume":"24","author":"Boado","year":"2007","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.addr.2024.115283_b0080","doi-asserted-by":"crossref","DOI":"10.1063\/5.0013178","article-title":"Microglia-targeting nanotherapeutics for neurodegenerative diseases","volume":"4","author":"Zhao","year":"2020","journal-title":"APL Bioeng"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11095-022-03433-5","article-title":"CNS delivery of nucleic acid therapeutics: beyond the blood-brain Barrier and Towards specific Cellular Targeting","volume":"40","author":"D'Souza","year":"2023","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.addr.2024.115283_b0090","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics - challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.addr.2024.115283_b0095","doi-asserted-by":"crossref","unstructured":"Lai, J. C.; Tan, W.; Benimetskaya, L.; Miller, P.; Colombini, M.; Stein, C. A. A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC. Proc Natl Acad Sci U S A 2006, 103 (19), 7494-7499. DOI: 10.1073\/pnas.0602217103 From NLM. Tan, W.; Loke, Y. H.; Stein, C. A.; Miller, P.; Colombini, M. Phosphorothioate oligonucleotides block the VDAC channel. Biophys J 2007, 93 (4), 1184-1191. DOI: 10.1529\/biophysj.107.105379 From NLM.","DOI":"10.1073\/pnas.0602217103"},{"issue":"8","key":"10.1016\/j.addr.2024.115283_b0100","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/cmdc.201000156","article-title":"Off-target effects related to the phosphorothioate modification of nucleic acids","volume":"5","author":"Winkler","year":"2010","journal-title":"ChemMedChem"},{"issue":"22","key":"10.1016\/j.addr.2024.115283_b0105","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1093\/nar\/gkn902","article-title":"Thermodynamic stability and Watson-crick base pairing in the seed duplex are major determinants of the efficiency of the siRNA-based off-target effect","volume":"36","author":"Ui-Tei","year":"2008","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.addr.2024.115283_b0110","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nbt.1543","article-title":"Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs","volume":"27","author":"Khan","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.addr.2024.115283_b0115","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/cts.12624","article-title":"Targeting RNA: a transformative therapeutic strategy","volume":"12","author":"Yin","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.addr.2024.115283_b0120","first-page":"161","article-title":"The limitless future of RNA therapeutics","author":"Damase","year":"2021","journal-title":"Frontiers in Bioengineering and Biotechnology"},{"key":"10.1016\/j.addr.2024.115283_b0125","doi-asserted-by":"crossref","unstructured":"Guo, P.; Haque, F.; Hallahan, B.; Reif, R.; Li, H. Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic acid therapeutics 2012, 22 (4), 226-245. Zhu, Y.; Zhu, L.; Wang, X.; Jin, H. RNA-based therapeutics: an overview and prospectus. Cell death & disease 2022, 13 (7), 644.","DOI":"10.1089\/nat.2012.0350"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0130","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/ijms24010746","article-title":"Clinical Pharmacokinetics of approved RNA therapeutics","volume":"24","author":"Jo","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"21","key":"10.1016\/j.addr.2024.115283_b0135","doi-asserted-by":"crossref","first-page":"e114760","DOI":"10.15252\/embj.2023114760","article-title":"RNA-based medicine: from molecular mechanisms to therapy","volume":"42","author":"Sparmann","year":"2023","journal-title":"The EMBO Journal"},{"issue":"10","key":"10.1016\/j.addr.2024.115283_b0140","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.tips.2020.08.004","article-title":"Paving the road for RNA therapeutics","volume":"41","author":"Dammes","year":"2020","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.addr.2024.115283_b0145","doi-asserted-by":"crossref","unstructured":"Juliano, R. L. Chemical Manipulation of the Endosome Trafficking Machinery: Implications for Oligonucleotide Delivery. Biomedicines 2021, 9 (5). DOI: 10.3390\/biomedicines9050512 From NLM.","DOI":"10.3390\/biomedicines9050512"},{"issue":"3","key":"10.1016\/j.addr.2024.115283_b0150","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/emmm.200900023","article-title":"RNAi-based therapeutics-current status, challenges and prospects","volume":"1","author":"Tiemann","year":"2009","journal-title":"EMBO Mol Med"},{"issue":"4","key":"10.1016\/j.addr.2024.115283_b0155","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1261\/rna.079507.122","article-title":"Endosomal escape of RNA therapeutics: how do we solve this rate-limiting problem?","volume":"29","author":"Dowdy","year":"2023","journal-title":"Rna"},{"issue":"5","key":"10.1016\/j.addr.2024.115283_b0160","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/nat.2022.0004","article-title":"Delivery of RNA therapeutics: the great endosomal escape!","volume":"32","author":"Dowdy","year":"2022","journal-title":"Nucleic Acid Ther"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/sj.gt.3303046","article-title":"Novel degradable oligoethylenimine acrylate ester-based pseudodendrimers for in vitro and in vivo gene transfer","volume":"15","author":"Russ","year":"2008","journal-title":"Gene Ther"},{"issue":"4","key":"10.1016\/j.addr.2024.115283_b0170","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/bc700463q","article-title":"Preparation and in vitro evaluation of novel lipopeptide transfection agents for efficient gene delivery","volume":"19","author":"Tarwadi","year":"2008","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.addr.2024.115283_b0175","doi-asserted-by":"crossref","unstructured":"Wickham, T. J.; Filardo, E. J.; Cheresh, D. A.; Nemerow, G. R. Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 1994, 127 (1), 257-264. DOI: 10.1083\/jcb.127.1.257 From NLM. Blumenthal, R.; Seth, P.; Willingham, M. C.; Pastan, I. pH-dependent lysis of liposomes by adenovirus. Biochemistry 1986, 25 (8), 2231-2237. DOI: 10.1021\/bi00356a057 From NLM.","DOI":"10.1083\/jcb.127.1.257"},{"issue":"7","key":"10.1016\/j.addr.2024.115283_b0180","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1517\/17425247.2016.1171315","article-title":"CSF, blood-brain barrier, and brain drug delivery","volume":"13","author":"Pardridge","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.addr.2024.115283_b0185","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2022.05.042","article-title":"Focused ultrasound\/microbubbles-assisted BBB opening enhances LNP-mediated mRNA delivery to brain","volume":"348","author":"Ogawa","year":"2022","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0190","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12987-023-00447-y","article-title":"Ultrasound-mediated blood-brain barrier opening uncovers an intracerebral perivenous fluid network in persons with Alzheimer's disease","volume":"20","author":"Mehta","year":"2023","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.addr.2024.115283_b0195","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2021.01.027","article-title":"Minimally invasive nasal depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain","volume":"331","author":"Padmakumar","year":"2021","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.addr.2024.115283_b0200","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s13311-013-0183-8","article-title":"Recent advances in RNA interference therapeutics for CNS diseases","volume":"10","author":"Ramachandran","year":"2013","journal-title":"Neurotherapeutics"},{"issue":"21","key":"10.1016\/j.addr.2024.115283_b0205","doi-asserted-by":"crossref","first-page":"9645","DOI":"10.1021\/acs.jmedchem.6b00551","article-title":"The medicinal chemistry of therapeutic oligonucleotides","volume":"59","author":"Wan","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"issue":"6","key":"10.1016\/j.addr.2024.115283_b0210","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/nat.2014.0506","article-title":"Phosphorothioates, essential components of therapeutic oligonucleotides","volume":"24","author":"Eckstein","year":"2014","journal-title":"Nucleic Acid Therapeutics"},{"key":"#cr-split#-10.1016\/j.addr.2024.115283_b0215.1","doi-asserted-by":"crossref","unstructured":"Prakash, T. P. An overview of sugar\u2010modified oligonucleotides for antisense therapeutics. Chemistry & biodiversity 2011, 8 (9), 1616-1641. Dirin, M.","DOI":"10.1002\/cbdv.201100081"},{"key":"#cr-split#-10.1016\/j.addr.2024.115283_b0215.2","doi-asserted-by":"crossref","unstructured":"Winkler, J. Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides. Expert opinion on biological therapy 2013, 13 (6), 875-888.","DOI":"10.1517\/14712598.2013.774366"},{"key":"10.1016\/j.addr.2024.115283_b0220","article-title":"Nucleic acid degradation as barrier to gene delivery: a guide to understand and overcome nuclease activity","author":"Zhang","year":"2024","journal-title":"Chemical Society Reviews"},{"key":"10.1016\/j.addr.2024.115283_b0225","doi-asserted-by":"crossref","unstructured":"Hoshika, S.; Minakawa, N.; Shionoya, A.; Imada, K.; Ogawa, N.; Matsuda, A. Study of modification pattern\u2013RNAi activity relationships by using siRNAs modified with 4\u2032\u2010Thioribonucleosides. ChemBioChem 2007, 8 (17), 2133-2138. Dande, P.; Prakash, T. P.; Sioufi, N.; Gaus, H.; Jarres, R.; Berdeja, A.; Swayze, E. E.; Griffey, R. H.; Bhat, B. Improving RNA interference in mammalian cells by 4 \u2018-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2 \u2018-O-alkyl modifications. Journal of medicinal chemistry 2006, 49 (5), 1624-1634. Gore, K. R.; Nawale, G. N.; Harikrishna, S.; Chittoor, V. G.; Pandey, S. K.; H\u00f6bartner, C.; Patankar, S.; Pradeepkumar, P. Synthesis, gene silencing, and molecular modeling studies of 4\u2032-C-aminomethyl-2\u2032-O-methyl modified small interfering RNAs. The Journal of Organic Chemistry 2012, 77 (7), 3233-3245.","DOI":"10.1021\/jm050822c"},{"key":"10.1016\/j.addr.2024.115283_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113900","article-title":"Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: getting the message across","volume":"176","author":"Minnaert","year":"2021","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.addr.2024.115283_b0235","doi-asserted-by":"crossref","unstructured":"Dong, Y.; Siegwart, D. J.; Anderson, D. G. Strategies, design, and chemistry in siRNA delivery systems. Advanced drug delivery reviews 2019, 144, 133-147. Aboul-Fadl, T. Antisense oligonucleotides: the state of the art. Current medicinal chemistry 2005, 12 (19), 2193-2214.","DOI":"10.2174\/0929867054864859"},{"issue":"5","key":"10.1016\/j.addr.2024.115283_b0240","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2012.08.002","article-title":"Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression","volume":"150","author":"Yu","year":"2012","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.addr.2024.115283_b0245","doi-asserted-by":"crossref","first-page":"e12122","DOI":"10.1371\/journal.pone.0012122","article-title":"Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra","volume":"5","author":"McCormack","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2024.115283_b0250","doi-asserted-by":"crossref","unstructured":"Jeong, J. H.; Mok, H.; Oh, Y. K.; Park, T. G. siRNA conjugate delivery systems. Bioconjug Chem 2009, 20 (1), 5-14. DOI: 10.1021\/bc800278e From NLM. Chernikov, I. V.; Vlassov, V. V.; Chernolovskaya, E. L. Current Development of siRNA Bioconjugates: From Research to the Clinic. Front Pharmacol 2019, 10, 444. DOI: 10.3389\/fphar.2019.00444 From NLM.","DOI":"10.3389\/fphar.2019.00444"},{"issue":"17","key":"10.1016\/j.addr.2024.115283_b0255","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1073\/pnas.86.17.6553","article-title":"Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture","volume":"86","author":"Letsinger","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"43","key":"10.1016\/j.addr.2024.115283_b0260","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.addr.2024.115283_b0265","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1038\/mtna.2016.50","article-title":"Docosahexaenoic acid conjugation enhances distribution and safety of siRNA upon local Administration in Mouse Brain","volume":"5","author":"Nikan","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.addr.2024.115283_b0270","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nbd.2019.03.001","article-title":"Systemic peptide mediated delivery of an siRNA targeting \u03b1-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of lewy body disease","volume":"127","author":"Spencer","year":"2019","journal-title":"Neurobiol Dis"},{"issue":"5","key":"10.1016\/j.addr.2024.115283_b0275","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.addr.2024.115283_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.900610","article-title":"Lipid-based nanoparticles and RNA as innovative neuro-therapeutics","volume":"13","author":"Tsakiri","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.addr.2024.115283_b0285","doi-asserted-by":"crossref","unstructured":"Xiong, R.; Ling, G.; Zhang, Y.; Guan, J.; Zhang, P. Nucleic acid delivery by ionizable nanocarriers for brain disease treatment. Brain\u2010X 2023, 1 (1), e7. Meng, Z.; O'Keeffe-Ahern, J.; Lyu, J.; Pierucci, L.; Zhou, D.; Wang, W. A new developing class of gene delivery: messenger RNA-based therapeutics. Biomater Sci 2017, 5 (12), 2381-2392. DOI: 10.1039\/c7bm00712d From NLM.","DOI":"10.1039\/C7BM00712D"},{"key":"10.1016\/j.addr.2024.115283_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101536","article-title":"Nanoparticle theranostics in cardiovascular inflammation","volume":"56","author":"MacRitchie","year":"2021","journal-title":"Semin Immunol"},{"issue":"6","key":"10.1016\/j.addr.2024.115283_b0295","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1021\/acs.molpharmaceut.0c00170","article-title":"Intranasal delivery and transfection of mRNA therapeutics in the brain using cationic liposomes","volume":"17","author":"Dhaliwal","year":"2020","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.addr.2024.115283_b0300","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2008.08.014","article-title":"Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS","volume":"132","author":"Cardoso","year":"2008","journal-title":"J Control Release"},{"issue":"7149","key":"10.1016\/j.addr.2024.115283_b0305","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nature05901","article-title":"Transvascular delivery of small interfering RNA to the central nervous system","volume":"448","author":"Kumar","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.addr.2024.115283_b0310","doi-asserted-by":"crossref","unstructured":"Knudsen, K. B.; Northeved, H.; Kumar, P. E.; Permin, A.; Gjetting, T.; Andresen, T. L.; Larsen, S.; Wegener, K. M.; Lykkesfeldt, J.; Jantzen, K.; et al. In vivo toxicity of cationic micelles and liposomes. Nanomedicine 2015, 11 (2), 467-477. DOI: 10.1016\/j.nano.2014.08.004 From NLM. Cui, S.; Wang, Y.; Gong, Y.; Lin, X.; Zhao, Y.; Zhi, D.; Zhou, Q.; Zhang, S. Correlation of the cytotoxic effects of cationic lipids with their headgroups. Toxicol Res (Camb) 2018, 7 (3), 473-479. DOI: 10.1039\/c8tx00005k From NLM. Kulkarni, J. A.; Witzigmann, D.; Thomson, S. B.; Chen, S.; Leavitt, B. R.; Cullis, P. R.; van der Meel, R. The current landscape of nucleic acid therapeutics. Nat Nanotechnol 2021, 16 (6), 630-643. DOI: 10.1038\/s41565-021-00898-0 From NLM.","DOI":"10.1038\/s41565-021-00898-0"},{"key":"10.1016\/j.addr.2024.115283_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.111028","article-title":"Actively targeted gold nanoparticle composites improve behavior and cognitive impairment in Parkinson's disease mice","volume":"114","author":"Liu","year":"2020","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"10.1016\/j.addr.2024.115283_b0320","doi-asserted-by":"crossref","unstructured":"Zou, Y.; Zhou, Q.; Zhao, Y.; Zhi, D.; Chen, H.; Wang, R.; Ju, B.; Zhang, S. Structure-activity relationships of pH-responsive and ionizable lipids for gene delivery. Int J Pharm 2022, 617, 121596. DOI: 10.1016\/j.ijpharm.2022.121596 From NLM. Tenchov, R.; Bird, R.; Curtze, A. E.; Zhou, Q. Lipid Nanoparticles\u2500From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano 2021, 15 (11), 16982-17015. DOI: 10.1021\/acsnano.1c04996 From NLM.","DOI":"10.1021\/acsnano.1c04996"},{"issue":"12","key":"10.1016\/j.addr.2024.115283_b0325","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1038\/mtna.2013.65","article-title":"Lipid Nanoparticle delivery of siRNA to silence neuronal gene expression in the brain","volume":"2","author":"Rungta","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.addr.2024.115283_b0330","doi-asserted-by":"crossref","unstructured":"Polack, F. P.; Thomas, S. J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J. L.; P\u00e9rez Marc, G.; Moreira, E. D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020, 383 (27), 2603-2615. DOI: 10.1056\/NEJMoa2034577 From NLM. Baden, L. R.; El Sahly, H. M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S. A.; Rouphael, N.; Creech, C. B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021, 384 (5), 403-416. DOI: 10.1056\/NEJMoa2035389 From NLM.","DOI":"10.1056\/NEJMoa2034577"},{"issue":"5","key":"10.1016\/j.addr.2024.115283_b0335","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1021\/acscentsci.1c00197","article-title":"Modifications in an emergency: the role of N1-methylpseudouridine in COVID-19 vaccines","volume":"7","author":"Nance","year":"2021","journal-title":"ACS Central Science"},{"key":"10.1016\/j.addr.2024.115283_b0340","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.587997","article-title":"Solid lipid Nanoparticles for drug delivery: Pharmacological and Biopharmaceutical aspects","volume":"7","author":"Scioli Montoto","year":"2020","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.addr.2024.115283_b0345","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.colsurfb.2017.01.031","article-title":"Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer's therapy","volume":"152","author":"Rassu","year":"2017","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.addr.2024.115283_b0350","doi-asserted-by":"crossref","unstructured":"Rai, R.; Alwani, S.; Badea, I. Polymeric Nanoparticles in Gene Therapy: New Avenues of Design and Optimization for Delivery Applications. Polymers (Basel) 2019, 11 (4). DOI: 10.3390\/polym11040745 From NLM. Kamaly, N.; Yameen, B.; Wu, J.; Farokhzad, O. C. Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release. Chem Rev 2016, 116 (4), 2602-2663. DOI: 10.1021\/acs.chemrev.5b00346 From NLM. Crucho, C. I. C.; Barros, M. T. Polymeric nanoparticles: A study on the preparation variables and characterization methods. Mater Sci Eng C Mater Biol Appl 2017, 80, 771-784. DOI: 10.1016\/j.msec.2017.06.004 From NLM. Elsabahy, M.; Wooley, K. L. Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev 2012, 41 (7), 2545-2561. DOI: 10.1039\/c2cs15327k From NLM. Bangde, P.; Atale, S.; Dey, A.; Pandit, A.; Dandekar, P.; Jain, R. Potential Gene Therapy Towards Treating Neurodegenerative Disea ses Employing Polymeric Nanosystems. Curr Gene Ther 2017, 17 (2), 170-183. DOI: 10.2174\/1566523217666170510153845 From NLM.","DOI":"10.2174\/1566523217666170510153845"},{"key":"10.1016\/j.addr.2024.115283_b0355","doi-asserted-by":"crossref","unstructured":"Siafaka, P. I.; Okur, M. E.; Erim, P. D.; \u00c7a\u011flar, E.; \u00d6zgen\u00e7, E.; G\u00fcndo\u011fdu, E.; K\u00f6pr\u00fcl\u00fc, R. E. P.; Karantas, I. D.; \u00dcst\u00fcnda\u011f Okur, N. Protein and Gene Delivery Systems for Neurodegenerative Disorders: Where Do We Stand Today? Pharmaceutics 2022, 14 (11). DOI: 10.3390\/pharmaceutics14112425 From NLM.","DOI":"10.3390\/pharmaceutics14112425"},{"key":"10.1016\/j.addr.2024.115283_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118449","article-title":"Rabies virus glycoprotein (RVG29)-linked microRNA-124-loaded polymeric nanoparticles inhibit neuroinflammation in a Parkinson's disease model","volume":"567","author":"Gan","year":"2019","journal-title":"Int J Pharm"},{"issue":"8","key":"10.1016\/j.addr.2024.115283_b0365","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/iub.2330","article-title":"Brain-targeted co-delivery of \u03b2-amyloid converting enzyme 1 shRNA and epigallocatechin-3-gallate by multifunctional nanocarriers for Alzheimer's disease treatment","volume":"72","author":"Lv","year":"2020","journal-title":"IUBMB Life"},{"key":"10.1016\/j.addr.2024.115283_b0370","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jconrel.2016.06.005","article-title":"MicroRNA-124 loaded nanoparticles enhance brain repair in Parkinson's disease","volume":"235","author":"Saraiva","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.addr.2024.115283_b0375","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.actbio.2016.11.029","article-title":"A hybrid siRNA delivery complex for enhanced brain penetration and precise amyloid plaque targeting in Alzheimer's disease mice","volume":"49","author":"Zheng","year":"2017","journal-title":"Acta Biomater"},{"key":"10.1016\/j.addr.2024.115283_b0380","unstructured":"Bayda, S.; Hadla, M.; Palazzolo, S.; Riello, P.; Corona, G.; Toffoli, G.; Rizzolio, F. Inorganic Nanoparticles for Cancer Therapy: A Transition from Lab to Clinic. Curr Med Chem 2018, 25 (34), 4269-4303. DOI: 10.2174\/0929867325666171229141156 From NLM. Kim, R.; Nam, Y. Fabrication of a nanoplasmonic chip to enhance neuron membrane potential imaging by metal-enhanced fluorescence effect. BioChip Journal 2021, 15, 171-178. Martano, S.; De Matteis, V.; Cascione, M.; Rinaldi, R. Inorganic Nanomaterials versus Polymer-Based Nanoparticles for Overcoming Neurodegeneration. Nanomaterials (Basel) 2022, 12 (14). DOI: 10.3390\/nano12142337 From NLM. Pandey, P.; Dahiya, M. A brief review on inorganic nanoparticles. J Crit Rev 2016, 3 (3), 18-26."},{"issue":"2","key":"10.1016\/j.addr.2024.115283_b0385","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7150\/thno.16562","article-title":"Inhibition by multifunctional magnetic Nanoparticles loaded with alpha-synuclein RNAi plasmid in a Parkinson's disease model","volume":"7","author":"Niu","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2024.115283_b0390","doi-asserted-by":"crossref","first-page":"27066","DOI":"10.3402\/jev.v4.27066","article-title":"Biological properties of extracellular vesicles and their physiological functions","volume":"4","author":"Y\u00e1\u00f1ez-M\u00f3","year":"2015","journal-title":"J Extracell Vesicles"},{"issue":"8","key":"10.1016\/j.addr.2024.115283_b0395","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/biosci\/biv084","article-title":"Extracellular vesicles: composition, biological relevance, and methods of study","volume":"65","author":"Zaborowski","year":"2015","journal-title":"Bioscience"},{"key":"10.1016\/j.addr.2024.115283_b0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.02.013","article-title":"Biogenesis and function of extracellular vesicles in cancer","volume":"188","author":"Bebelman","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.addr.2024.115283_b0405","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, K.; Breyne, K.; Ughetto, S.; Laurent, L. C.; Breakefield, X. O. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nature reviews Molecular cell biology 2020, 21 (10), 585-606. Maas, S. L.; Breakefield, X. O.; Weaver, A. M. Extracellular vesicles: unique intercellular delivery vehicles. Trends in cell biology 2017, 27 (3), 172-188.","DOI":"10.1038\/s41580-020-0251-y"},{"issue":"15","key":"10.1016\/j.addr.2024.115283_b0410","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1039\/C9TB00170K","article-title":"Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges","volume":"7","author":"Zhang","year":"2019","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.addr.2024.115283_b0415","first-page":"1","article-title":"Entry and exit of extracellular vesicles to and from the blood circulation","author":"Iannotta","year":"2023","journal-title":"Nature Nanotechnology"},{"issue":"12","key":"10.1016\/j.addr.2024.115283_b0420","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1089\/hum.1998.9.12-1769","article-title":"Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses","volume":"9","author":"Puumalainen","year":"1998","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0425","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/gt.2015.75","article-title":"Evaluation of helper-dependent canine adenovirus vectors in a 3D human CNS model","volume":"23","author":"Sim\u00e3o","year":"2016","journal-title":"Gene Ther"},{"key":"10.1016\/j.addr.2024.115283_b0430","first-page":"15","article-title":"Engineering adenoviral vectors with improved GBM selectivity","author":"Bates","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.addr.2024.115283_b0435","doi-asserted-by":"crossref","unstructured":"Wheeler, L. A.; Manzanera, A. G.; Bell, S. D.; Cavaliere, R.; McGregor, J. M.; Grecula, J. C.; Newton, H. B.; Lo, S. S.; Badie, B.; Portnow, J.; et al. Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. Neuro Oncol 2016, 18 (8), 1137-1145. DOI: 10.1093\/neuonc\/now002 From NLM. Ji, N.; Weng, D.; Liu, C.; Gu, Z.; Chen, S.; Guo, Y.; Fan, Z.; Wang, X.; Chen, J.; Zhao, Y. Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma. Oncotarget 2016, 7 (4), 4369.","DOI":"10.1093\/neuonc\/now002"},{"issue":"4","key":"10.1016\/j.addr.2024.115283_b0440","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/neuonc\/noy202","article-title":"Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma","volume":"21","author":"Kieran","year":"2019","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.addr.2024.115283_b0445","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2217\/fon-2019-0743","article-title":"Study protocol of a phase I\/IIa clinical trial of ad-SGE-REIC for treatment of recurrent malignant glioma","volume":"16","author":"Kurozumi","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.addr.2024.115283_b0450","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11596-013-1136-5","article-title":"Effects of small interfering RNA targeting sphingosine kinase-1 gene on the animal model of Alzheimer\u2019s disease","volume":"33","author":"Zhang","year":"2013","journal-title":"Journal of Huazhong University of Science and Technology [medical Sciences]"},{"key":"10.1016\/j.addr.2024.115283_b0455","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.lfs.2018.08.030","article-title":"Silencing of PHLPP1 promotes neuronal apoptosis and inhibits functional recovery after spinal cord injury in mice","volume":"209","author":"Shao","year":"2018","journal-title":"Life Sci"},{"issue":"4","key":"10.1016\/j.addr.2024.115283_b0460","first-page":"5601","article-title":"Adenoviruses-mediated RNA interference targeting cytosolic phospholipase A2\u03b1 attenuates focal ischemic brain damage in mice","volume":"17","author":"Wu","year":"2018","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0465","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12975-020-00809-w","article-title":"Knockdown of arginyl-tRNA synthetase attenuates ischemia-induced cerebral cortex injury in rats after middle cerebral artery occlusion","volume":"12","author":"Liu","year":"2021","journal-title":"Transl Stroke Res"},{"issue":"6","key":"10.1016\/j.addr.2024.115283_b0470","first-page":"840","article-title":"Inhibition of sonic hedgehog signaling inhibits fibrous scar formation and adversely affects functional outcome after ischemic brain injury in rats","volume":"42","author":"Wen","year":"2022","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"10","key":"10.1016\/j.addr.2024.115283_b0475","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/sc.2016.20","article-title":"Effect of adenovirus-mediated RNA interference of IL-1\u03b2 expression on spinal cord injury in rats","volume":"54","author":"Lin","year":"2016","journal-title":"Spinal Cord"},{"issue":"22","key":"10.1016\/j.addr.2024.115283_b0480","doi-asserted-by":"crossref","first-page":"12243","DOI":"10.1128\/JVI.78.22.12243-12251.2004","article-title":"Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death","volume":"78","author":"Abou El Hassan","year":"2004","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.addr.2024.115283_b0485","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.canlet.2015.06.002","article-title":"MT1-MMP silencing by an shRNA-armed glioma-targeted conditionally replicative adenovirus (CRAd) improves its anti-glioma efficacy in vitro and in vivo","volume":"365","author":"Ulasov","year":"2015","journal-title":"Cancer Lett"},{"issue":"3685","key":"10.1016\/j.addr.2024.115283_b0490","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-associated defective virus particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"key":"10.1016\/j.addr.2024.115283_b0495","series-title":"SiRNA delivery methods. methods in Molecular","author":"Shum","year":"2016"},{"key":"10.1016\/j.addr.2024.115283_b0500","doi-asserted-by":"crossref","unstructured":"Foust, K. D.; Nurre, E.; Montgomery, C. L.; Hernandez, A.; Chan, C. M.; Kaspar, B. K. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009, 27 (1), 59-65. DOI: 10.1038\/nbt.1515 From NLM. Tanguy, Y.; Biferi, M. G.; Besse, A.; Astord, S.; Cohen-Tannoudji, M.; Marais, T.; Barkats, M. Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice. Front Mol Neurosci 2015, 8, 36. DOI: 10.3389\/fnmol.2015.00036 From NLM. Bourdenx, M.; Dutheil, N.; Bezard, E.; Dehay, B. Systemic gene delivery to the central nervous system using Adeno-associated virus. Front Mol Neurosci 2014, 7, 50. DOI: 10.3389\/fnmol.2014.00050 From NLM.","DOI":"10.3389\/fnmol.2014.00050"},{"issue":"9","key":"10.1016\/j.addr.2024.115283_b0505","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1089\/hum.2011.008","article-title":"Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery","volume":"22","author":"Snyder","year":"2011","journal-title":"Hum Gene Ther"},{"issue":"7","key":"10.1016\/j.addr.2024.115283_b0510","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/mt.2014.68","article-title":"Global CNS transduction of adult mice by intravenously delivered rAAVrh. 8 and rAAVrh.10 and nonhuman primates by rAAVrh.10","volume":"22","author":"Yang","year":"2014","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.addr.2024.115283_b0515","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.ajpath.2013.02.030","article-title":"Chronic neuron- and age-selective down-regulation of TNF receptor expression in triple-transgenic Alzheimer disease mice leads to significant modulation of amyloid- and tau-related pathologies","volume":"182","author":"Montgomery","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.addr.2024.115283_b0520","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.nbd.2014.09.013","article-title":"AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo","volume":"73","author":"Saal","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"5","key":"10.1016\/j.addr.2024.115283_b0525","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/mds.27695","article-title":"Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia","volume":"34","author":"Steece-Collier","year":"2019","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.addr.2024.115283_b0530","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s00018-022-04444-6","article-title":"Altered m6A RNA methylation contributes to hippocampal memory deficits in Huntington's disease mice","volume":"79","author":"Pupak","year":"2022","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"10.1016\/j.addr.2024.115283_b0535","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s11596-016-1623-6","article-title":"Stereotactic injection of shrna GSK-3\u03b2-AAV promotes axonal regeneration after spinal cord injury","volume":"36","author":"Zuo","year":"2016","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"issue":"12","key":"10.1016\/j.addr.2024.115283_b0540","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1002\/mds.28750","article-title":"Striatal cholinergic dysregulation after neonatal decrease in X-linked dystonia Parkinsonism-related TAF1 isoforms","volume":"36","author":"Cirnaru","year":"2021","journal-title":"Mov Disord"},{"key":"10.1016\/j.addr.2024.115283_b0545","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jare.2022.11.007","article-title":"Maf1 is an intrinsic suppressor against spontaneous neural repair and functional recovery after ischemic stroke","volume":"51","author":"Tsang","year":"2023","journal-title":"J Adv Res"},{"issue":"9","key":"10.1016\/j.addr.2024.115283_b0550","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/j.ymthe.2021.04.025","article-title":"Microglial lnc-U90926 facilitates neutrophil infiltration in ischemic stroke via MDH2\/CXCL2 axis","volume":"29","author":"Chen","year":"2021","journal-title":"Mol Ther"},{"issue":"11","key":"10.1016\/j.addr.2024.115283_b0555","doi-asserted-by":"crossref","first-page":"6701","DOI":"10.1007\/s12035-022-03000-4","article-title":"LncRNA Tug1 contributes post-stroke NLRP3 inflammasome-dependent pyroptosis via miR-145a-5p\/Tlr4 Axis","volume":"59","author":"Yao","year":"2022","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.addr.2024.115283_b0560","series-title":"Introduction to viral vectors and other delivery methods for gene therapy of the nervous system","first-page":"3","author":"Manfredsson","year":"2016"},{"key":"10.1016\/j.addr.2024.115283_b0565","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nbd.2019.04.015","article-title":"Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics","volume":"129","author":"Stanek","year":"2019","journal-title":"Neurobiol Dis"},{"issue":"3","key":"10.1016\/j.addr.2024.115283_b0570","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3233\/JHD-160215","article-title":"Cellular analysis of silencing the Huntington\u2019s disease gene using AAV9 mediated delivery of artificial micro RNA into the striatum of Q140\/Q140 mice","volume":"5","author":"Keeler","year":"2016","journal-title":"Journal of Huntington's Disease"},{"issue":"10","key":"10.1016\/j.addr.2024.115283_b0575","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gt.2017.71","article-title":"AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease","volume":"24","author":"Miniarikova","year":"2017","journal-title":"Gene Ther"},{"issue":"1\u20132","key":"10.1016\/j.addr.2024.115283_b0580","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/hum.2021.221","article-title":"Efficient and Precise processing of the optimized Primary artificial MicroRNA in a huntingtin-lowering adeno-associated viral gene therapy in vitro and in mice and nonhuman primates","volume":"33","author":"Wang","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.addr.2024.115283_b0585","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.brainres.2018.10.025","article-title":"Efficient RNA interference-based knockdown of mutant torsinA reveals reversibility of PERK-eIF2\u03b1 pathway dysregulation in DYT1 transgenic rats in vivo","volume":"1706","author":"Beauvais","year":"2019","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.addr.2024.115283_b0590","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1089\/nat.2021.0020","article-title":"miRNA-mediated knockdown of ATXN3 alleviates Molecular disease Hallmarks in a mouse model for Spinocerebellar ataxia type 3","volume":"32","author":"Nobre","year":"2022","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"10.1016\/j.addr.2024.115283_b0595","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ana.24618","article-title":"Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model","volume":"79","author":"Stoica","year":"2016","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.addr.2024.115283_b0600","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/neuonc\/nox138","article-title":"microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis","volume":"20","author":"Bhere","year":"2018","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.addr.2024.115283_b0605","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/pcmedi\/pbab021","article-title":"CRISPR\/Cas9 mediated somatic gene therapy for insertional mutations: the vibrator mouse model","volume":"4","author":"Fu","year":"2021","journal-title":"Precis Clin Med"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0610","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1038\/s41467-021-26518-y","article-title":"Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo","volume":"12","author":"Ibraheim","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.addr.2024.115283_b0615","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ymthe.2019.08.005","article-title":"SINEUP non-coding RNA Targeting GDNF rescues motor deficits and neurodegeneration in a mouse model of Parkinson's disease","volume":"28","author":"Espinoza","year":"2020","journal-title":"Mol Ther"},{"issue":"10","key":"10.1016\/j.addr.2024.115283_b0620","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1128\/JVI.74.10.4612-4620.2000","article-title":"Design and packaging of adeno-associated virus gene targeting vectors","volume":"74","author":"Hirata","year":"2000","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.addr.2024.115283_b0625","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/mt.2016.152","article-title":"Somatic therapy of a mouse SMA model with a U7 snRNA gene correcting SMN2 splicing","volume":"24","author":"Odermatt","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.addr.2024.115283_b0630","doi-asserted-by":"crossref","unstructured":"Li, H.; Okada, H.; Suzuki, S.; Sakai, K.; Izumi, H.; Matsushima, Y.; Ichinohe, N.; Goto, Y. I.; Okada, T.; Inoue, K. Gene suppressing therapy for Pelizaeus-Merzbacher disease using artificial microRNA. JCI Insight 2019, 4 (10). DOI: 10.1172\/jci.insight.125052 From NLM.","DOI":"10.1172\/jci.insight.125052"},{"issue":"569","key":"10.1016\/j.addr.2024.115283_b0635","doi-asserted-by":"crossref","first-page":"eaba9188","DOI":"10.1126\/scitranslmed.aba9188","article-title":"MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates","volume":"12","author":"Hordeaux","year":"2020","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0640","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1038\/s41467-023-38582-7","article-title":"Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates","volume":"14","author":"Chen","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0645","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.medj.2022.11.002","article-title":"Systemic administration of novel engineered AAV capsids facilitates enhanced transgene expression in the macaque CNS","volume":"4","author":"Stanton","year":"2023","journal-title":"Med"},{"issue":"11","key":"10.1016\/j.addr.2024.115283_b0650","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/s41591-021-01522-3","article-title":"Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain","volume":"27","author":"Keiser","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.addr.2024.115283_b0655","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.omtm.2022.09.002","article-title":"Selection of rAAV vectors that cross the human blood-brain barrier and target the central nervous system using a transwell model","volume":"27","author":"Song","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0660","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41598-017-01635-1","article-title":"Engineered HSV vector achieves safe long-term transgene expression in the central nervous system","volume":"7","author":"Verlengia","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.addr.2024.115283_b0665","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.omtm.2021.03.020","article-title":"Improvement of HSV-1 based amplicon vectors for a safe and long-lasting gene therapy in non-replicating cells","volume":"21","author":"Soukupov\u00e1","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0670","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/mt.2014.177","article-title":"Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV","volume":"23","author":"Mazzacurati","year":"2015","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.addr.2024.115283_b0675","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.addr.2024.115283_b0680","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.2174\/13894501113146660213","article-title":"Lentiviral vectors: a powerful tool to target astrocytes in vivo","volume":"14","author":"Delzor","year":"2013","journal-title":"Curr Drug Targets"},{"issue":"3","key":"10.1016\/j.addr.2024.115283_b0685","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/humc.2018.081","article-title":"Long-term follow-up of a phase I\/II study of ProSavin, a lentiviral vector gene therapy for Parkinson's disease","volume":"29","author":"Palfi","year":"2018","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.addr.2024.115283_b0690","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.895713","article-title":"Viral vectors for the in vivo delivery of CRISPR components: advances and challenges","volume":"10","author":"Asmamaw Mengstie","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0695","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1038\/s41598-020-68257-y","article-title":"Transcriptional repression of PTEN in neural cells using CRISPR\/dCas9 epigenetic editing","volume":"10","author":"Moses","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0700","doi-asserted-by":"crossref","first-page":"5447","DOI":"10.1038\/s41598-018-23751-2","article-title":"Lentiviral vector delivery of short hairpin RNA to NgR1 promotes nerve regeneration and locomotor recovery in injured rat spinal cord","volume":"8","author":"Zhao","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0705","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12974-018-1286-2","article-title":"Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease","volume":"15","author":"Williams","year":"2018","journal-title":"J Neuroinflammation"},{"issue":"3","key":"10.1016\/j.addr.2024.115283_b0710","first-page":"2080","article-title":"Knockdown of BACE1-AS by siRNA improves memory and learning behaviors in Alzheimer's disease animal model","volume":"16","author":"Zhang","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.addr.2024.115283_b0715","doi-asserted-by":"crossref","unstructured":"Balakrishnan, A.; Roy, S.; Fleming, T.; Leong, H. S.; Schuurmans, C. The Emerging Role of Extracellular Vesicles in the Glioma Microenvironment: Biogenesis and Clinical Relevance. Cancers (Basel) 2020, 12 (7). DOI: 10.3390\/cancers12071964 From NLM.","DOI":"10.3390\/cancers12071964"},{"issue":"10","key":"10.1016\/j.addr.2024.115283_b0720","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1038\/mtna.2013.60","article-title":"Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity","volume":"2","author":"Munoz","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"10.1016\/j.addr.2024.115283_b0725","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1158\/0008-5472.CAN-13-2650","article-title":"Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1","volume":"74","author":"Bronisz","year":"2014","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.addr.2024.115283_b0730","doi-asserted-by":"crossref","first-page":"e2713","DOI":"10.1038\/cddis.2017.117","article-title":"Cell-based therapy using miR-302-367 expressing cells represses glioblastoma growth","volume":"8","author":"Fareh","year":"2017","journal-title":"Cell Death Dis"},{"issue":"1\u20132","key":"10.1016\/j.addr.2024.115283_b0735","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jneuroim.2013.10.014","article-title":"IFN\u03b3-stimulated dendritic cell exosomes as a potential therapeutic for remyelination","volume":"266","author":"Pusic","year":"2014","journal-title":"J Neuroimmunol"},{"issue":"6","key":"10.1016\/j.addr.2024.115283_b0740","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.1021\/acsnano.9b01004","article-title":"Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative Disorders","volume":"13","author":"Riazifar","year":"2019","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0745","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12951-020-00630-5","article-title":"MicroRNA-421-3p-abundant small extracellular vesicles derived from M2 bone marrow-derived macrophages attenuate apoptosis and promote motor function recovery via inhibition of mTOR in spinal cord injury","volume":"18","author":"Wang","year":"2020","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.addr.2024.115283_b0750","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.omtn.2020.06.013","article-title":"Therapeutic effects of simultaneous delivery of nerve growth factor mRNA and protein via exosomes on cerebral ischemia","volume":"21","author":"Yang","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"10.1016\/j.addr.2024.115283_b0755","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41467-018-03733-8","article-title":"Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson's disease treatment","volume":"9","author":"Kojima","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.addr.2024.115283_b0760","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.omtn.2017.04.010","article-title":"Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia","volume":"7","author":"Yang","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"10.1016\/j.addr.2024.115283_b0765","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"12","key":"10.1016\/j.addr.2024.115283_b0770","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/mds.25978","article-title":"Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice","volume":"29","author":"Cooper","year":"2014","journal-title":"Mov Disord"},{"issue":"10","key":"10.1016\/j.addr.2024.115283_b0775","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/mt.2016.126","article-title":"Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing","volume":"24","author":"Didiot","year":"2016","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.addr.2024.115283_b0780","doi-asserted-by":"crossref","first-page":"10015","DOI":"10.1021\/acsnano.9b01892","article-title":"Intranasal delivery of mesenchymal stem cell derived exosomes loaded with phosphatase and tensin homolog siRNA repairs complete spinal cord injury","volume":"13","author":"Guo","year":"2019","journal-title":"ACS Nano"},{"issue":"5","key":"10.1016\/j.addr.2024.115283_b0785","doi-asserted-by":"crossref","first-page":"20200190","DOI":"10.1002\/VIW.20200190","article-title":"Consideration for the scale-up manufacture of nanotherapeutics\u2014A critical step for technology transfer","volume":"2","author":"Liu","year":"2021","journal-title":"View"},{"issue":"10","key":"10.1016\/j.addr.2024.115283_b0790","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical trial and Postmarketing safety of onasemnogene Abeparvovec therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.addr.2024.115283_b0795","doi-asserted-by":"crossref","unstructured":"Cott, E.; deBruyn, E.; Corum, J. How Pfizer makes its COVID-19 vaccine. The New York Times 2021, 28-04. Evers, M. J.; Kulkarni, J. A.; van der Meel, R.; Cullis, P. R.; Vader, P.; Schiffelers, R. M. State\u2010of\u2010the\u2010art design and rapid\u2010mixing production techniques of lipid nanoparticles for nucleic acid delivery. Small Methods 2018, 2 (9), 1700375. Shepherd, S. J.; Han, X.; Mukalel, A. J.; El-Mayta, R.; Thatte, A. S.; Wu, J.; Padilla, M. S.; Alameh, M. G.; Srikumar, N.; Lee, D.; et al. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines. Proc Natl Acad Sci U S A 2023, 120 (33), e2303567120. DOI: 10.1073\/pnas.2303567120 From NLM.","DOI":"10.1073\/pnas.2303567120"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X24001054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X24001054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T11:49:35Z","timestamp":1716810575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X24001054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":160,"alternative-id":["S0169409X24001054"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2024.115283","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA therapies for CNS diseases","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2024.115283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115283"}}